Tezepelumab, a drug being developed by AstraZeneca in collaboration with Amgen, has been granted orphan drug status in the United States. The drug is intended to treat eosinophilic esophagitis. This status is granted to drugs used to treat, diagnose, or prevent rare diseases or disorders.